Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
w decrease » we decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
Showing 121 - 140 results of 100,486 for search '(( 5 ((a decrease) OR (nn decrease)) ) OR ( 5 ((w decrease) OR (mean decrease)) ))', query time: 0.94s Refine Results
  1. 121
    Blocking C5L2 decreased C5a-primed neutrophils expression of membrane-bound PR3 (mPR3).

    Blocking C5L2 decreased C5a-primed neutrophils expression of membrane-bound PR3 (mPR3). by Jian Hao (160736)

    Published 2013
    Save to List
    Saved in:
  2. 122
    S5 Fig -

    S5 Fig - by Jordan K. Abbott (8934239)

    Published 2022
    Save to List
    Saved in:
  3. 123
    5-FU induces a decrease in the total cell number in cultures of smooth muscle cells.

    5-FU induces a decrease in the total cell number in cultures of smooth muscle cells. by Marcelo de Carvalho Filgueiras (408321)

    Published 2013
    “…Quantification of the number of nuclei per field revealed that 5-FU treatment induced a decrease in cell number in all the concentrations tested (<b>G</b>). …”
    Save to List
    Saved in:
  4. 124
    Variability is correlated with increasing repeat length, increasing purity, and decreasing unit size.

    Variability is correlated with increasing repeat length, increasing purity, and decreasing unit size. by John W. Fondon III (145820)

    Published 2013
    Save to List
    Saved in:
  5. 125
    Mutation of Ser-473 in GC-A to alanine but not glutamate decreases ANP-stimulated guanylyl cyclase activity.

    Mutation of Ser-473 in GC-A to alanine but not glutamate decreases ANP-stimulated guanylyl cyclase activity. by Andrea R. Yoder (165684)

    Published 2012
    Save to List
    Saved in:
  6. 126
    Structure of YOLOv5s-SBC.

    Structure of YOLOv5s-SBC. by Zhongjian Xie (4633099)

    Published 2024
    “…Compared to the original model, P-YOLOv5s-GRNF decreased parameters by 18%, decreased model size to 11.9MB, decreased FLOPs to 14.5G, and increased FPS by 4.3. …”
    Save to List
    Saved in:
  7. 127
    Fluoxetine decreases TOPFlash firefly luciferase reporter activity.

    Fluoxetine decreases TOPFlash firefly luciferase reporter activity. by Kentaro Miyamoto (123271)

    Published 2017
    Save to List
    Saved in:
  8. 128
    Early increase and later decrease in GSK-3β activity.

    Early increase and later decrease in GSK-3β activity. by Arie J. Hoogendijk (353624)

    Published 2013
    Save to List
    Saved in:
  9. 129
    Conventional dynamic latch comparator [13], [14].

    Conventional dynamic latch comparator [13], [14]. by Labonnah Farzana Rahman (641767)

    Published 2014
    Subjects:
    Save to List
    Saved in:
  10. 130
    Performance comparison of the proposed dynamic latch comparator.

    Performance comparison of the proposed dynamic latch comparator. by Labonnah Farzana Rahman (641767)

    Published 2014
    Subjects:
    Save to List
    Saved in:
  11. 131
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 132
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 133
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 134
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 135
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 136
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 137
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 138
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 139
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 140
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: